DALLAS, Sept. 18, 2019 /PRNewswire/ — Medecision, an integrated health management solutions company that supports the health and care of more than 50 million consumers nationwide, is excited to announce the formation of its Advisory Board. Medecision’s Advisory Board is comprised of healthcare and technology leaders who share a passion for and dedication to liberating healthcare by helping consumers engage effortlessly and efficiently with their care teams and caregivers. The Advisory Board provides insights and facilitates relationships for Medecision’s leadership teams in advancement of the company’s strategic goals.
The Advisory Board is chaired by Richard Popiel, MD, MBA, a clinical and business executive who most recently served as an executive vice president at Cambia Health Solutions where he helped the company transform into a powerhouse regional consumer brand. Now an advisor to leading industry stakeholders and disruptors such as BioIQ, Tabula Rasa Healthcare and Pager, Dr. Popiel informs on key industry trends such as digital engagement investment and optimal consumer management. Previously, he was the Chief Medical Officer at Horizon Blue Cross Blue Shield.
“Medecision has evolved to provide the high-touch, high-tech platform and services for today’s productive engagement of members, patients and their care systems,” said Richard Popiel. “I am energized by the opportunity to help this leadership team advance a path to new levels of population and individual activation, in collaboration with some of the best minds and strongest voices in the industry.”
“Bold, courageous and tireless are some of the characteristics required to tackle the biggest challenges in our industry, and each Advisory Board member exudes those characteristics in spades,” said Deborah Gage, Medecision President and CEO. “We now have access to the industry’s best insights as we expand the impact of our solutions on the health and care of one in six Americans and hundreds of thousands of clinical and community caregivers. I am personally thrilled to be working alongside each of these Advisory Board members in pursuit of our mission to liberate healthcare.”
Chair-elect on the board is Jan Berger, MD, MJ, an executive whose career focuses on making care ecosystem workflows smarter and more efficient for better patient and population health outcomes is in sync with the progressive value of Medecision’s flagship solution, Aerial™. Dr. Berger is a board member to Cambia Health Solutions, GNS Healthcare, UCB, Savor Health, Voluntis and Tabula Rasa, and a former Chief Medical Officer of CVS Caremark.
Drs. Popiel and Berger are joined by other Advisory Board members, including:
The company expects to add members to its Advisory Board throughout 2019.
About Medecision
At Medecision, we believe in a liberated healthcare system where people, plans and care teams engage in driving the best health outcomes in a seamless, interconnected way. That’s why we invest every year in delivering a better Aerial™ experience to our customers and the people they serve. See how the Aerial Experience enables better health and care for people like Joan, Mack and Margaret, who want to thrive while managing chronic conditions. With more than 30 years of business success under our belt, and more than 50 million lives under Aerial management, we know what it takes to power success for our clients – more than 85 of the leading health plans and systems in the US. With our professional services division, Aveus, we tackle complex challenges in our pursuit to drive the best consumer experience. Learn more about our mission, vision, team and achievements by visiting medecision.com or follow us on LinkedIn.
Media contact:
Regena Frieden
Regena.Frieden@medecision.com
480.258.9232
View original content to download multimedia:http://www.prnewswire.com/news-releases/medecision-appoints-advisory-board-300920195.html
SOURCE Medecision
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the…
LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of…
TUCSON, Ariz., Dec. 27, 2024 (GLOBE NEWSWIRE) -- via IBN – WEED Inc. (OTCQB: BUDZ), (“WEED,”…
STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “Company”),…
VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP…
Wuxi, China, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Park Ha Biological Technology Co., Ltd. (the…